

## Supplementary

**Table S1** Univariate and multivariate competing-risks regression analysis of risk factors associated with recurrence in the entire cohort

| Variables                        | HR comparison                    | UV HR (95% CI)   | UV P value | MV HR (95% CI)   | MV P value |
|----------------------------------|----------------------------------|------------------|------------|------------------|------------|
| Age                              | >60 vs. ≤60 years                | 0.93 (0.83–1.05) | 0.270      |                  |            |
| Gender                           | Male vs. Female                  | 1.26 (1.09–1.47) | 0.003      | 1.23 (1.05–1.44) | 0.007      |
| ASA score                        | >2 vs. ≤2                        | 0.92 (0.79–1.07) | 0.280      |                  |            |
| HBV (+)                          | HBV vs. non-HBV                  | 1.08 (0.95–1.23) | 0.230      |                  |            |
| HCV (+)                          | HCV vs. non-HCV                  | 0.99 (0.85–1.17) | 0.960      |                  |            |
| Cirrhosis                        | Yes vs. No                       | 1.21 (1.10–1.34) | <0.001     | 1.23 (1.11–1.37) | <0.001     |
| Child-Pugh grade                 | B vs. A                          | 1.06 (0.78–1.41) | 0.720      |                  |            |
| Preoperative hemoglobin          | <110 vs. ≥110 g/dL               | 0.94 (0.71–1.24) | 0.660      |                  |            |
| Preoperative platelet counts     | <100 vs. ≥100×10 <sup>9</sup> /L | 0.93 (0.81–1.08) | 0.360      |                  |            |
| Preoperative AFP                 | >400 vs. ≤400 µg/L               | 1.19 (1.07–1.33) | 0.001      | 1.05 (0.94–1.18) | 0.280      |
| Maximum tumor size               | >5 vs. ≤5 cm                     | 1.44 (1.31–1.59) | <0.001     | 1.23 (1.08–1.40) | <0.001     |
| Tumor number                     | Multiple vs. Solitary            | 1.64 (1.46–1.85) | <0.001     | 1.37 (1.19–1.58) | <0.001     |
| Satellite nodules                | Yes vs. No                       | 1.46 (1.32–1.61) | <0.001     | 1.15 (1.01–1.31) | <0.001     |
| Tumor encapsulation              | Incomplete vs. Complete          | 1.34 (1.17–1.54) | <0.001     | 1.21 (1.05–1.41) | <0.001     |
| Tumor differentiation            | Poor vs. Well or moderate        | 1.25 (1.11–1.42) | <0.001     | 1.04 (1.01–1.18) | <0.001     |
| Microvascular invasion           | Yes vs. No                       | 1.39 (1.25–1.54) | <0.001     | 1.13 (1.01–1.27) | <0.001     |
| Extent of hepatectomy            | Major vs. Minor                  | 1.46 (1.30–1.64) | <0.001     | 1.13 (0.97–1.31) | 0.316      |
| Type of hepatectomy              | Non-anatomical vs. Anatomical    | 1.18 (1.05–1.32) | 0.004      | 0.97 (0.85–1.11) | 0.760      |
| Resection margin                 | <1.0 vs. ≥1.0 cm                 | 1.10 (0.99–1.21) | 0.064      | 1.08 (0.98–1.20) | 0.873      |
| Intraoperative blood loss        | >600 vs. ≤600 mL                 | 1.26 (1.07–1.48) | 0.005      | 1.06 (0.89–1.27) | 0.230      |
| Intraoperative blood transfusion | Yes vs. No                       | 1.43 (1.22–1.67) | <0.001     | 1.11 (0.93–1.32) | 0.107      |
| Application of Pringle maneuver  | No vs. Yes                       | 0.77 (0.66–0.91) | 0.001      | 0.82 (0.70–0.97) | 0.011      |

ASA, American Society of Anesthesiologists; AFP, alpha-fetoprotein; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; MV, multivariate; UV, univariate.

**Table S2** Univariate and multivariate competing-risks regression analysis of risk factors associated with recurrence in the PSM cohort.

| Variables                        | HR comparison                    | UV HR (95% CI)   | UV P value | MV HR (95% CI)   | MV P value |
|----------------------------------|----------------------------------|------------------|------------|------------------|------------|
| Age                              | >60 vs. ≤60 years                | 0.95 (0.82–1.12) | 0.570      |                  |            |
| Gender                           | Male vs. Female                  | 1.27 (1.05–1.54) | 0.016      | 1.25 (1.02–1.53) | 0.026      |
| ASA score                        | >2 vs. ≤2                        | 0.97 (0.79–1.19) | 0.770      |                  |            |
| HBV (+)                          | HBV vs. non-HBV                  | 1.14 (0.94–1.37) | 0.170      |                  |            |
| HCV (+)                          | HCV vs. non-HCV                  | 0.94 (0.74–1.20) | 0.650      |                  |            |
| Cirrhosis                        | Yes vs. No                       | 1.19 (1.04–1.36) | 0.009      | 1.15 (1.00–1.33) | 0.042      |
| Child-Pugh grade                 | B vs. A                          | 1.03 (0.64–1.66) | 0.890      |                  |            |
| Preoperative hemoglobin          | <110 vs. ≥110 g/dL               | 1.09 (0.79–1.49) | 0.600      |                  |            |
| Preoperative platelet counts     | <100 vs. ≥100×10 <sup>9</sup> /L | 0.90 (0.75–1.08) | 0.250      |                  |            |
| Preoperative AFP                 | >400 vs. ≤400 µg/L               | 1.14 (0.98–1.32) | 0.075      | 1.00 (0.86–1.17) | 0.940      |
| Maximum tumor size               | >5 vs. ≤5 cm                     | 1.45 (1.26–1.67) | <0.001     | 1.22 (1.00–1.50) | 0.048      |
| Tumor number                     | Multiple vs. Solitary            | 1.61 (1.37–1.91) | <0.001     | 1.37 (1.12–1.68) | 0.001      |
| Satellite nodules                | Yes vs. No                       | 1.37 (1.19–1.56) | <0.001     | 1.07 (0.90–1.27) | 0.400      |
| Tumor encapsulation              | Incomplete vs. Complete          | 1.26 (1.06–1.51) | 0.010      | 1.11 (0.92–1.34) | 0.250      |
| Tumor differentiation            | Poor vs. Well or moderate        | 1.39 (1.17–1.66) | <0.001     | 1.20 (0.99–1.45) | 0.058      |
| Microvascular invasion           | Yes vs. No                       | 1.42 (1.23–1.65) | <0.001     | 1.20 (1.02–1.41) | 0.029      |
| Extent of hepatectomy            | Major vs. Minor                  | 1.47 (1.25–1.72) | <0.001     | 1.12 (0.88–1.43) | 0.320      |
| Type of hepatectomy              | Non-anatomical vs. Anatomical    | 1.07 (0.92–1.25) | 0.360      |                  |            |
| Resection margin                 | <1.0 vs. ≥1.0 cm                 | 1.22 (1.07–1.40) | 0.003      | 1.23 (1.07–1.41) | 0.003      |
| Intraoperative blood loss        | >600 vs. ≤600 mL                 | 1.28 (1.04–1.56) | 0.017      | 1.05 (0.85–1.31) | 0.630      |
| Intraoperative blood transfusion | Yes vs. No                       | 1.38 (1.13–1.67) | 0.001      | 1.06 (0.83–1.32) | 0.640      |
| Application of Pringle maneuver  | No vs. Yes                       | 0.81 (0.68–0.95) | 0.012      | 0.80 (0.67–0.95) | 0.012      |

ASA, American Society of Anesthesiologists; AFP, alpha-fetoprotein; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; MV, multivariate; PSM, propensity score matching; UV, univariate.

**Table S3** Univariate and multivariate competing-risks regression analysis of risk factors associated with cancer-specific mortality (CSM) in the entire cohort

| Variables                        | HR comparison                    | UV HR (95% CI)   | UV P value | MV HR (95% CI)   | MV P value |
|----------------------------------|----------------------------------|------------------|------------|------------------|------------|
| Age                              | >60 vs. ≤60 years                | 0.89 (0.76–1.05) | 0.170      |                  |            |
| Gender                           | Male vs. Female                  | 1.23 (1.02–1.50) | 0.034      | 1.20 (0.97–1.46) | 0.240      |
| ASA score                        | >2 vs. ≤2                        | 0.93 (0.76–1.13) | 0.480      |                  |            |
| HBV (+)                          | HBV vs. non-HBV                  | 1.09 (0.92–1.29) | 0.300      |                  |            |
| HCV (+)                          | HCV vs. non-HCV                  | 0.96 (0.78–1.19) | 0.750      |                  |            |
| Cirrhosis                        | Yes vs. No                       | 1.30 (1.14–1.49) | <0.001     | 1.26 (1.09–1.44) | 0.015      |
| Child-Pugh grade                 | B vs. A                          | 0.98 (0.66–1.46) | 0.940      |                  |            |
| Preoperative hemoglobin          | <110 vs. ≥110 g/dL               | 1.09 (0.79–1.50) | 0.570      |                  |            |
| Preoperative platelet counts     | <100 vs. ≥100×10 <sup>9</sup> /L | 0.87 (0.73–1.05) | 0.150      |                  |            |
| Preoperative AFP                 | >400 vs. ≤400 µg/L               | 1.49 (1.31–1.70) | <0.001     | 1.18 (1.02–1.35) | 0.001      |
| Maximum tumor size               | >5 vs. ≤5 cm                     | 2.06 (1.81–2.34) | <0.001     | 1.50 (1.26–1.77) | <0.001     |
| Tumor number                     | Multiple vs. Solitary            | 1.93 (1.68–2.23) | <0.001     | 1.39 (1.16–1.65) | <0.001     |
| Satellite nodules                | Yes vs. No                       | 1.83 (1.61–2.08) | <0.001     | 1.33 (1.12–1.58) | <0.001     |
| Tumor encapsulation              | Incomplete vs. Complete          | 1.48 (1.22–1.79) | <0.001     | 1.15 (0.94–1.39) | 0.090      |
| Tumor differentiation            | Poor vs. Well or moderate        | 1.84 (1.52–2.23) | <0.001     | 1.33 (1.08–1.62) | 0.001      |
| Microvascular invasion           | Yes vs. No                       | 1.75 (1.54–2.00) | <0.001     | 1.23 (1.06–1.42) | <0.001     |
| Extent of hepatectomy            | Major vs. Minor                  | 1.97 (1.71–2.26) | <0.001     | 1.28 (1.07–1.52) | <0.001     |
| Type of hepatectomy              | Non-anatomical vs. Anatomical    | 1.54 (1.31–1.80) | <0.001     | 1.08 (0.90–1.29) | 0.306      |
| Resection margin                 | <1.0 vs. ≥1.0 cm                 | 1.06 (0.93–1.20) | 0.390      |                  |            |
| Intraoperative blood loss        | >600 vs. ≤600 mL                 | 1.38 (1.14–1.68) | <0.001     | 1.06 (0.86–1.31) | 0.939      |
| Intraoperative blood transfusion | Yes vs. No                       | 1.91 (1.60–2.27) | <0.001     | 1.32 (0.97–1.52) | 0.091      |
| Application of Pringle maneuver  | No vs. Yes                       | 0.68 (0.55–0.84) | <0.001     | 0.77 (0.61–0.96) | 0.031      |

ASA, American Society of Anesthesiologists; AFP, alpha-fetoprotein; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; MV, multivariate; UV, univariate.

**Table S4** Univariate and multivariate competing-risks regression analysis of risk factors associated with cancer-specific mortality (CSM) in the PSM cohort

| Variables                        | HR comparison                    | UV HR (95% CI)     | UV P value | MV HR (95% CI)     | MV P value |
|----------------------------------|----------------------------------|--------------------|------------|--------------------|------------|
| Age                              | >60 vs. ≤60 years                | 0.94 (0.75–1.16)   | 0.570      |                    |            |
| Gender                           | Male vs. Female                  | 1.22 (0.94–1.57)   | 0.120      |                    |            |
| ASA score                        | >2 vs. ≤2                        | 1.00 (0.76–1.32)   | 0.980      |                    |            |
| HBV (+)                          | HBV vs. non-HBV                  | 1.05 (0.82–1.34)   | 0.680      |                    |            |
| HCV (+)                          | HCV vs. non-HCV                  | 1.07 (0.80–1.42)   | 0.650      |                    |            |
| Cirrhosis                        | Yes vs. No                       | 1.35 (1.13–1.61)   | <0.001     | 1.34 (1.11–1.62)   | 0.001      |
| Child-Pugh grade                 | B vs. A                          | 1.19 (0.68 – 2.07) | 0.540      |                    |            |
| Preoperative hemoglobin          | <110 vs. ≥110 g/dL               | 1.25 (0.86–1.81)   | 0.230      |                    |            |
| Preoperative platelet counts     | <100 vs. ≥100×10 <sup>9</sup> /L | 0.85 (0.69–1.06)   | 0.160      |                    |            |
| Preoperative AFP                 | >400 vs. ≤400 µg/L               | 1.44 (1.20–1.73)   | <0.001     | 1.10 (0.91–1.34)   | 0.300      |
| Maximum tumor size               | >5 vs. ≤5 cm                     | 2.16 (1.81–2.57)   | <0.001     | 1.52 (1.17 – 1.98) | 0.001      |
| Tumor number                     | Multiple vs. Solitary            | 1.83 (1.49–2.25)   | <0.001     | 1.32 (1.03–1.70)   | 0.026      |
| Satellite nodules                | Yes vs. No                       | 2.76 (1.48–2.10)   | <0.001     | 1.29 (1.03–1.61)   | 0.023      |
| Tumor encapsulation              | Incomplete vs. Complete          | 1.47 (1.15–1.89)   | 0.002      | 1.11 (0.86–1.45)   | 0.400      |
| Tumor differentiation            | Poor vs. Well or moderate        | 2.19 (1.66–2.88)   | <0.001     | 1.60 (1.19–2.14)   | 0.001      |
| Microvascular invasion           | Yes vs. No                       | 1.88 (1.57–2.25)   | <0.001     | 1.26 (1.02–1.55)   | 0.027      |
| Extent of hepatectomy            | Major vs. Minor                  | 2.22 (1.84–2.68)   | <0.001     | 1.41 (1.05–1.88)   | 0.019      |
| Type of hepatectomy              | Non-anatomical vs. Anatomical    | 1.23 (0.99–1.51)   | 0.051      | 0.92 (0.73–1.16)   | 0.520      |
| Resection margin                 | <1.0 vs. ≥1.0 cm                 | 1.20 (1.00–1.43)   | 0.046      | 1.20 (0.99–1.45)   | 0.051      |
| Intraoperative blood loss        | >600 vs. ≤600 mL                 | 1.33 (1.04–1.70)   | 0.025      | 0.90 (0.68–1.19)   | 0.480      |
| Intraoperative blood transfusion | Yes vs. No                       | 1.90 (1.52–2.37)   | <0.001     | 1.21 (0.92–1.59)   | 0.160      |
| Application of Pringle maneuver  | No vs. Yes                       | 0.73 (0.58–0.92)   | 0.007      | 0.73 (0.58–0.92)   | 0.006      |

ASA, American Society of Anesthesiologists; AFP, alpha-fetoprotein; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; MV, multivariate; PSM, propensity score matching; UV, univariate.

**Table 5** Univariate and multivariate regression analysis of risk factors associated with recurrence in the IPTW cohort


| Variables                        | HR comparison                    | UV HR (95% CI)   | UV P value | MV HR (95% CI)   | MV P value |
|----------------------------------|----------------------------------|------------------|------------|------------------|------------|
| Age                              | >60 vs. ≤60 years                | 0.91 (0.74–1.13) | 0.417      |                  |            |
| Gender                           | Male vs. Female                  | 1.52 (1.12–2.07) | 0.007      | 1.47 (1.10–1.95) | 0.007      |
| ASA score                        | >2 vs. ≤2                        | 0.89 (0.70–1.12) | 0.345      |                  |            |
| HBV (+)                          | HBV vs. non-HBV                  | 0.92 (0.74–1.15) | 0.490      |                  |            |
| HCV (+)                          | HCV vs. non-HCV                  | 1.05 (0.79–1.38) | 0.719      |                  |            |
| Cirrhosis                        | Yes vs. No                       | 1.25 (1.05–1.51) | 0.013      | 1.26 (1.05–1.51) | 0.011      |
| Child-Pugh grade                 | B vs. A                          | 0.92 (0.51–1.67) | 0.794      |                  |            |
| Preoperative hemoglobin          | <110 vs. ≥110 g/dL               | 1.31 (0.87–1.97) | 0.181      |                  |            |
| Preoperative platelet counts     | <100 vs. ≥100×10 <sup>9</sup> /L | 0.95 (0.74–1.22) | 0.725      |                  |            |
| Preoperative AFP                 | >400 vs. ≤400 µg/L               | 1.30 (1.03–1.65) | 0.025      | 1.13 (0.91–1.39) | 0.243      |
| Maximum tumor size               | >5 vs. ≤5 cm                     | 1.37 (1.13–1.66) | 0.001      | 1.26 (1.01–1.52) | 0.046      |
| Tumor number                     | Multiple vs. Solitary            | 1.62 (1.26–2.08) | <0.001     | 1.21 (0.93–1.58) | 0.138      |
| Satellite nodules                | Yes vs. No                       | 1.70 (1.40–2.06) | <0.001     | 1.31 (1.06–1.62) | 0.012      |
| Tumor encapsulation              | Incomplete vs. Complete          | 1.36 (1.07–1.73) | 0.011      | 1.14 (0.90–1.45) | 0.258      |
| Tumor differentiation            | Poor vs. Well or moderate        | 1.41 (1.10–1.82) | 0.006      | 1.07 (0.84–1.37) | 0.541      |
| Microvascular invasion           | Yes vs. No                       | 1.80 (1.48–2.19) | <0.001     | 1.38 (1.11–1.71) | 0.002      |
| Extent of hepatectomy            | Major vs. Minor                  | 1.54 (1.26–1.89) | <0.001     | 1.14 (0.86–1.51) | 0.319      |
| Type of hepatectomy              | Non-anatomical vs. Anatomical    | 1.25 (0.98–1.59) | 0.068      | 1.03 (0.80–1.32) | 0.829      |
| Resection margin                 | <1.0 vs. ≥1.0 cm                 | 1.27 (1.07–1.50) | 0.004      | 0.98 (0.81–1.18) | 0.849      |
| Intraoperative blood loss        | >600 vs. ≤600 mL                 | 1.40 (1.01–1.94) | 0.041      | 1.15 (0.89–1.50) | 0.263      |
| Intraoperative blood transfusion | Yes vs. No                       | 1.32 (0.97–1.80) | 0.074      | 1.01 (0.78–1.30) | 0.916      |
| Application of Pringle maneuver  | No vs. Yes                       | 0.80 (0.66–0.98) | 0.035      | 0.80 (0.66–0.97) | 0.029      |

ASA, American Society of Anesthesiologists; AFP, alpha-fetoprotein; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; IPTW, inverse probability of treatment weight; MV, multivariate; UV, univariate.


**Table S6** Univariate and multivariate regression analysis of risk factors associated with CSM in the IPTW cohort

| Variables                        | HR comparison                    | UV HR (95% CI)     | UV P value | MV HR (95% CI)   | MV P value |
|----------------------------------|----------------------------------|--------------------|------------|------------------|------------|
| Age                              | >60 vs. ≤60 years                | 0.95 (0.70–1.27)   | 0.738      |                  |            |
| Gender                           | Male vs. Female                  | 1.69 (1.15–2.47)   | 0.006      | 1.54 (1.07–2.20) | 0.018      |
| ASA score                        | >2 vs. ≤2                        | 0.90 (0.63–1.25)   | 0.550      |                  |            |
| HBV (+)                          | HBV vs. non-HBV                  | 1.01 (0.73–1.40)   | 0.909      |                  |            |
| HCV (+)                          | HCV vs. non-HCV                  | 0.86 (0.58–1.27)   | 0.461      |                  |            |
| Cirrhosis                        | Yes vs. No                       | 1.42 (1.13–1.79)   | 0.003      | 1.56 (1.23–1.98) | <0.001     |
| Child-Pugh grade                 | B vs. A                          | 1.05 (0.59–1.86)   | 0.865      |                  |            |
| Preoperative hemoglobin          | <110 vs. ≥110 g/dL               | 1.01 (0.99–1.01)   | 0.732      |                  |            |
| Preoperative platelet counts     | <100 vs. ≥100×10 <sup>9</sup> /L | 1.06 (0.76–1.49)   | 0.714      |                  |            |
| Preoperative AFP                 | >400 vs. ≤400 µg/L               | 1.71 (1.32–2.22)   | <0.001     | 1.27 (1.01–1.59) | 0.044      |
| Maximum tumor size               | >5 vs. ≤5 cm                     | 2.23 (1.76–2.81)   | <0.001     | 1.98 (1.44–2.71) | <0.001     |
| Tumor number                     | Multiple vs. Solitary            | 1.96 (1.45–2.62)   | <0.001     | 1.13 (0.84–1.52) | 0.404      |
| Satellite nodules                | Yes vs. No                       | 2.43 (1.93–3.07)   | <0.001     | 1.70 (1.32–2.19) | <0.001     |
| Tumor encapsulation              | Incomplete vs. Complete          | 1.51 (1.06–2.15)   | 0.021      | 1.02 (0.73–1.42) | 0.872      |
| Tumor differentiation            | Poor vs. Well or moderate        | 2.19 (1.47–3.26)   | <0.001     | 1.34 (0.91–1.98) | 0.130      |
| Microvascular invasion           | Yes vs. No                       | 2.62 (2.08–3.27)   | <0.001     | 1.68 (1.31–2.15) | <0.001     |
| Extent of hepatectomy            | Major vs. Minor                  | 2.21 (1.74–2.81)   | <0.001     | 1.31 (0.96–1.79) | 0.086      |
| Type of hepatectomy              | Non-anatomical vs. Anatomical    | 1.57 (1.12–2.21)   | 0.008      | 0.99 (0.70–1.39) | 0.970      |
| Resection margin                 | <1.0 vs. ≥1.0 cm                 | 1.43 (1.15 – 1.77) | <0.001     | 0.89 (0.70–1.13) | 0.367      |
| Intraoperative blood loss        | >600 vs. ≤600 mL                 | 1.44 (1.06 – 1.97) | 0.019      | 0.89 (0.65–1.22) | 0.478      |
| Intraoperative blood transfusion | Yes vs. No                       | 1.74 (1.29–2.33)   | <0.001     | 1.15 (0.88–1.51) | 0.286      |
| Application of Pringle maneuver  | No vs. Yes                       | 0.75 (0.57–0.99)   | 0.043      | 0.76 (0.59–0.98) | 0.044      |

ASA, American Society of Anesthesiologists; AFP, alpha-fetoprotein; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; IPTW, inverse probability of treatment weight; MV, multivariate; UV, univariate.



**Figure S1** Study flowchart. HCC, hepatocellular carcinoma; PM, Pringle maneuver.



**Figure S2** Comparisons of standardized mean difference of clinical variables between patients with and without the application of Pringle maneuver in the entire cohort (red dots), in the PSM cohort (green dots), and in the IPTW cohort (blue dots), respectively. ASA, American Society of Anesthesiologists; IPTW, inverse probability of treatment weight; PSM, propensity score matching.